These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 23896824)

  • 21. Tacrolimus plus low-dose mycophenolate mofetil in renal transplant recipients: better 2-year graft and patient survival than with a higher mycophenolate mofetil dose.
    Kocak H; Yakupoglu U; Karatas GU; Yavuz A; Gurkan A; Erdogan O; Ersoy FF; Yakupoglu G; Demirbas A; Tuncer M
    Transplant Proc; 2005 Sep; 37(7):3009-11. PubMed ID: 16213288
    [TBL] [Abstract][Full Text] [Related]  

  • 22. De novo sirolimus with low-dose tacrolimus versus full-dose tacrolimus with mycophenolate mofetil after heart transplantation--8-year results.
    Guethoff S; Stroeh K; Grinninger C; Koenig MA; Kleinert EC; Rieger A; Mayr T; von Ziegler F; Reichart B; Hagl C; Schramm R; Kaczmarek I; Meiser BM
    J Heart Lung Transplant; 2015 May; 34(5):634-42. PubMed ID: 25701373
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomized, multicenter trial comparing tacrolimus plus mycophenolate mofetil to tacrolimus plus steroids in hepatitis C virus-positive recipients of living donor liver transplantation.
    Takada Y; Kaido T; Asonuma K; Sakurai H; Kubo S; Kiuchi T; Inomata Y; Isaji S; Tsumura H; Teramukai S; Matsubara Y; Sakabayashi S; Uemoto S
    Liver Transpl; 2013 Aug; 19(8):896-906. PubMed ID: 23696054
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patient outcomes in two steroid-free regimens using tacrolimus monotherapy after daclizumab induction and tacrolimus with mycophenolate mofetil in liver transplantation.
    Becker T; Foltys D; Bilbao I; D'Amico D; Colledan M; Bernardos A; Beckebaum S; Isoniemi H; Pirenne J; Jaray J;
    Transplantation; 2008 Dec; 86(12):1689-94. PubMed ID: 19104406
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term maintenance immunosuppressive regimen with tacrolimus monotherapy.
    Augusto JF; Subra JF; Onno C; Villemain F; Croue A; Dussaussoy C; Picquet J; Coeffic B; Sayegh J
    Ann Transplant; 2013 Jul; 18():368-77. PubMed ID: 23872516
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term outcome of azathioprine versus mycophenolate mofetil in cyclosporine-based immunosuppression in kidney transplantation: 10 years of experience at a single center.
    Kwon O; Cho JH; Choi JY; Park SH; Kim YL; Kim HK; Huh S; Kim CD
    Transplant Proc; 2013 May; 45(4):1487-90. PubMed ID: 23726603
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Initial clinical experience with interleukin-2 receptor antagonist induction in combination with tacrolimus, mycophenolate mofetil and steroids in simultaneous kidney-pancreas transplantation.
    Lo A; Stratta RJ; Alloway RR; Egidi MF; Shokouh-Amiri MH; Grewal HP; Gaber LW; Gaber AO
    Transpl Int; 2001 Dec; 14(6):396-404. PubMed ID: 11793037
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplantation with tacrolimus and steroid avoidance: four-year analysis.
    Ciancio G; Gaynor JJ; Zarak A; Sageshima J; Guerra G; Roth D; Brown R; Kupin W; Chen L; Tueros L; Hanson L; Ruiz P; Burke GW
    Transplantation; 2011 Jun; 91(11):1198-205. PubMed ID: 21107305
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The impact of mycophenolate mofetil versus azathioprine as adjunctive therapy to cyclosporine on the rates of renal allograft loss due to glomerular disease recurrence.
    Pham PT; Pham PC
    Nephrol Dial Transplant; 2012 Jul; 27(7):2965-71. PubMed ID: 22207327
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preventing cardiac allograft vasculopathy: long-term beneficial effects of mycophenolate mofetil.
    Kaczmarek I; Ertl B; Schmauss D; Sadoni S; Knez A; Daebritz S; Meiser B; Reichart B
    J Heart Lung Transplant; 2006 May; 25(5):550-6. PubMed ID: 16678034
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is mycophenolate mofetil less safe than azathioprine in elderly renal transplant recipients?
    Johnson DW; Nicol DL; Purdie DM; Preston JM; Brown AM; Hawley CM; Campbell SB; Wall D; Griffin AD; Isbel NM
    Transplantation; 2002 Apr; 73(7):1158-63. PubMed ID: 11965051
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanistic analyses in kidney transplant recipients prospectively randomized to two steroid free regimen-Low dose Tacrolimus with Everolimus versus standard dose Tacrolimus with Mycophenolate Mofetil.
    Traitanon O; Mathew JM; Shetty A; Bontha SV; Maluf DG; El Kassis Y; Park SH; Han J; Ansari MJ; Leventhal JR; Mas V; Gallon L
    PLoS One; 2019; 14(5):e0216300. PubMed ID: 31136582
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mycophenolate mofetil in low-risk renal transplantation in patients receiving no cyclosporine: a single-centre experience.
    Raheem OA; Daly PJ; O'Kelly P; Shields WP; Zimmerman AJ; Mohan P; Power R; Little DM; Conlon PJ; Hickey DP
    Nephrol Dial Transplant; 2012 Feb; 27(2):840-4. PubMed ID: 21622991
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cyclosporine A versus tacrolimus in combination with mycophenolate mofetil and steroids as primary immunosuppression after lung transplantation: one-year results of a 2-center prospective randomized trial.
    Zuckermann A; Reichenspurner H; Birsan T; Treede H; Deviatko E; Reichart B; Klepetko W
    J Thorac Cardiovasc Surg; 2003 Apr; 125(4):891-900. PubMed ID: 12698153
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/thymoglobulin: one year follow-up.
    Ciancio G; Burke GW; Gaynor JJ; Roth D; Sageshima J; Kupin W; Tueros L; Hanson L; Rosen A; Ruiz P; Miller J
    Transplantation; 2008 Jul; 86(1):67-74. PubMed ID: 18622280
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tacrolimus plus mycophenolate mofetil vs. cyclosporine plus everolimus in deceased donor kidney transplant recipients: three-yr results of a single-center prospective clinical trial.
    Favi E; Spagnoletti G; Salerno MP; Pedroso JA; Romagnoli J; Citterio F
    Clin Transplant; 2013; 27(4):E359-67. PubMed ID: 23710603
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mycophenolic acid dose reductions result in poor long-term renal allograft survival: comparison between mycophenolate sodium and mycophenolate mofetil.
    Laftavi MR; Hai F; Laftavi H; Feng L; Said M; Patel S; Kohli R; Alnimri M; Dayton M; Pankewycz O
    Transplant Proc; 2011 Mar; 43(2):478-81. PubMed ID: 21440738
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tacrolimus/mycophenolate mofetil improved natural killer lymphocyte reconstitution one year after kidney transplant by reference to cyclosporine/azathioprine.
    Vacher-Coponat H; Brunet C; Moal V; Loundou A; Bonnet E; Lyonnet L; Ravet S; Sampol-Manos E; Sampol J; Berland Y; George FD; Paul P
    Transplantation; 2006 Aug; 82(4):558-66. PubMed ID: 16926601
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunosuppression modifications and graft outcome in patients with chronic allograft nephropathy.
    El-Agroudy AE; El-Dahshan K; Mahmoud K; Ismail AM; El-Baz M; Shokeir AA; Ghoneim MA
    Exp Clin Transplant; 2008 Sep; 6(3):203-10. PubMed ID: 18954298
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lung Transplant Outcomes in Adults in the United States: Retrospective Cohort Study Using Real-world Evidence from the SRTR.
    Erdman J; Wolfram J; Nimke D; Croy R; Wang X; Weaver T; Schladt D; Fitzsimmons WE
    Transplantation; 2022 Jun; 106(6):1233-1242. PubMed ID: 34974456
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.